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Aim: We sought to survey a large, multi-center patient sample to better characterize/quantify
RT  utilization at the end of life.
Background: Few objective data exist for radiation therapy (RT) delivery at end of life (EOL).
Materials and methods: Data were retrieved for all patients receiving RT in calendar year 2010
in  the Department of Radiation Oncology at Indiana University (IU) and Howard University
(HU) hospitals. Speciﬁc attention was made of the group of patients receiving RT in the last
30  days of life.
Results: A total of 852 patients received all or part of their RT during 2010 (HU: 139, IU: 713).
At  time of analysis in early 2012, 179 patients had died (21%). Fifty-four patients (6.3% of
total; 30% of expired patients) died within 30 days of receiving their last treatment. Twenty
patients (2.3% of total; 11.2% of expired patients) received RT within their last week of life.
For  both sites, the median time until death from completion of therapy was 12.5 days (range
2–30  days).
Conclusions: Radiation in the last month of life is likely to provide minimal palliation or
survival beneﬁt. This, coupled with the ﬁnancial implications, time investment, and physicalcosts, suggests that physicians and patients should more strongly consider hospice, and
minimize duration of palliative RT courses as far as possible. As with chemotherapy, RT
utilization at EOL should be considered for collection as an overuse metric.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
ent practices. In fact, one international survey suggested.  Background
uch  of the modern practice of radiation therapy (RT)
s palliative. Despite this, there are remarkably few data
escribing RT at end-of-life (EOL).1–5 With few national
uidelines6,7 to unify medical opinion on such practice,
 Previously presented, in part, at American Radium Society Annual C
∗ Corresponding author at: Department of Radiation Oncology, Indiana
napolis, IN 46202, United States. Tel.: +1 317 944 2425; fax: +1 317 944 
E-mail address: pajohnst@iupui.edu (P.A.S. Johnstone).
507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
ttp://dx.doi.org/10.1016/j.rpor.2013.09.010rights reserved.
and minimal research describing efﬁcacy of RT at EOL,
it may be expected that there is a large variance in
the treatment of terminally ill patients between differ-onference, 5/2012, Las Vegas, NV, United States.
 University School of Medicine, 535 Barnhill Drive (RT041), Indi-
2486.
the existence of more  than 100 different fractionation
schemes used for patients treated with radiotherapy for bone
metastases.8
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Summary of patient data.
IU HU
Total patients 713 139
Expired within 30 days of RT 44/6.2% 10/7.2%
Expired within 7 days of RT 16/2.2% 4/2.9%
Deﬁnitive cases dying within 30 days 4 3
Causes MI (2);
sepsis;
prog dz
MI, sepsis,
unk
Aborted courses 12/1.7% 5/3.6%
Mean fx delivered/prescribed 4.5/10 19/30
IU, Indiana University; HU, Howard University.192  reports of practical oncology an
Hospice care aims to provide palliation of symptoms for
patients whose expected disease course involves less than
a 6 month life expectancy. Still, oncologists have sometimes
been reluctant to refer patients for hospice consultation,
and the average length of stay of oncology patients in hos-
pice remains quite short.9 ASCO’s Quality Oncology Practice
Initiative (QOPI)10 has established a framework to guide
management with chemotherapeutic agents in terminally ill
patients. Chemotherapy provided within the last 2 weeks of
life, as well as treatment courses initiated within 1 month
of death are consistent with overutilization of chemother-
apy. These practices were found to be associated with worse
quality of life, with more  intensive care unit admissions and
more  emergency department visits while failing to improve
outcomes. One study compared a group of cancer patients
including about 10% receiving chemotherapy at the EOL to
another group of cancer patients containing 2% receiving
EOL chemotherapy. The group with more  EOL chemotherapy
patients had a more  than double rate of ICU admissions.11,12
Additionally, patients randomized to a palliative care consult
at the time of diagnosis with non-small cell lung cancer tended
to receive less chemotherapy and had a greater life expectancy
than those who  did not.13
No similar comprehensive scales like QOPI currently exist
for RT. While chemotherapy at the end of life has been declared
to be overaggressive, RT continued into or initiated during
this timeframe has not been clearly discouraged in a simi-
lar fashion. Admittedly, a single fraction of 8 Gy may provide
signiﬁcant palliation of bone pain; but longer fractionation
schemes likely have minimal additional palliative effect and
confer no increase in survival. Thus, it is critical to analyze
existing RT practices in terminal patients.
2.  Aim
We  undertook a benchmarking analysis to report the fre-
quency of RT utilization for patients at EOL.
3.  Materials  and  methods
To create a diverse sample set of patients encompassing a wide
distribution of diagnoses, socioeconomic status, and stages
of disease, all patients treated with RT in the 2010 calendar
year were included in our cross-sectional study. The Institu-
tional Review Boards at IU and HU provided approval for this
retrospective analysis to be performed at those sites.
Several assumptions were made in interpreting these data.
First, we assumed that radiation oncologists treated patients
with the belief that they would beneﬁt from RT. In other
words, we assumed that no one was delivered RT consid-
ered a priori to be futile. Secondly, we assumed that briefer
courses, generally of larger daily fraction sizes, were more  fre-
quently palliative than curative. This is of course subject to
amendment based on the histology being treated. Frequency
of palliative vs. deﬁnitive RT, sites of treatment, and speciﬁcs
of concurrent chemotherapy, hormonal therapy or antibiotic
therapy were speciﬁcally assumed to be similarly distributed
between these two tertiary care facilities over the period of an
entire year.Prior to data collection, the sample’s scope was narrowed
to deceased patients only, and then among those who  had
deceased, only those who had passed away within 4 weeks of
RT were considered for further analysis. Outcomes of interest
that were deﬁned prior to analysis were survival time post-
treatment, oncologic diagnosis, and intention of treatment.
Outcomes explored after collecting data included treatment
timeframes, and received vs. prescribed dosage.
Dates of death for deceased patients were retrieved from
the Social Security Death Index, and the date of death com-
pared with the recorded last day of RT. Patients expiring within
30 days of receiving radiation therapy were selected for further
analysis.
4.  Results
Data are tabulated in Table 1. Brieﬂy, at IU, 713 total patients
received RT in 2010, of which 142 (19.9%) had died at time of
analysis (summer, 2012). Of these 142 deceased, 44 patients
(31%) died within 1 month of their last treatment. Of all 713
RT patients at IU in 2010, 6% died within a month of receiving
treatment. At HU, 37 of the 139 total patients (26.6%) had died
at time of analysis; ten of those 37 (27%) died within 1 month
of their last treatment. Of all 139 RT patients at HU in 2010,
7% died within a month of receiving RT. There were no deaths
due to RT toxicity.
At IU, of the 44 patients dying within 1 month of their last
treatment, 16 patients (36.4%) received RT within their last
week of life. At HU, of the ten patients who had expired within
30 days of RT, four patients (40%) received RT during the last
week of life. The median time until death from completion of
therapy was 12.5 days (range 2–30 days) at IU; at HU it was 12
days (range 3–29 days).
Deﬁnitive cases were less likely to die within 30 days of
treatment. Four IU patients died while receiving deﬁnitive
therapy: one patient undergoing chemoradiation for vulvar
carcinoma died of sepsis, another died of small cell lung can-
cer, and two died of myocardial infarction. Three HU patients
died while receiving deﬁnitive therapy.
At IU, 10 of the patients treated within 1 month of death
had RT halted prematurely for worsening performance sta-
tus, after a median 4.5 fractions of 10 prescribed. At HUH,
4 EOL RT patients had RT halted prematurely for worsen-
ing performance status or for noncompliance, after a median
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9 fractions of a median of 30 fractions prescribed (mean
7 Gy/45 Gy prescribed).
.  Conclusions
OL issues are extraordinarily complex. Even something a con-
eptually simple as assigning “Do Not Resuscitate” status has
astly different ramiﬁcations for the patient, their loved ones,
nd health care team.14 The proportion of patients receiving
hemotherapy in the United States within 14 days of death
ose from 9.7% in 1993 to 11.6% in 1999.15 Justiﬁable concerns
bout this trend led to national initiatives such as QOPI to
iminish what is perceived to be futile care. No such national
ata exist for RT. In determining appropriateness of RT at EOL,
t is important to acknowledge the minimal palliative beneﬁt
nd nonexistent survival beneﬁt of radiating these patients.
nly then, presuming a widening acceptance and use of hos-
ice, can the national discussion begin about what aspects of
T at EOL may rightly be considered futile.
We  previously published results of a pilot trial of patients
resented at departmental Morbidity & Mortality (M&M)
onference.1 Of 63 patients receiving RT within 30 days of
eath, over half were still on treatment at time of death, and
ost of them were less than halfway through the prescribed
ourse of RT. The inherent bias stemming from sampling from
oor outcomes, wrought by this pilot study’s sample being
elected from among M&M  cases, compelled us to broaden
he study population to include an entire year’s patients in a
ulti-institutional setting to provide a clearer perspective.
Gripp et al.2 showed that among a set of patients receiv-
ng RT at the end of life, half of the patients actually had
orsening symptoms despite palliative treatment intention.
nly one quarter had improvement of their symptoms prior
o death and the other quarter of the patients died while on
reatment. In this group, half of cancer patients dying within
0 days of hospital admission had received daily radiation for
ore  than 60% of their remaining life, and the median dura-
ion of RT was equal to the median survival of that cohort at
5 days. In our previous report on a select patient group,1 over
alf (52%) of patients were still on treatment until the time of
heir death, with six patients receiving a treatment on the day
f their death. Over half (54%) of patients had completed less
han half of their original radiation therapy plan at the time
f death and over one-ﬁfth of patients were under treatment
or more  than half of their last month of life.
Kapadia and associates3 analyzed data between 2007 and
010 from the National Comprehensive Cancer Network Non-
mall Cell Lung Cancer Outcomes Database Project, reporting
hat 10% of patients who  died had received EOL RT. Nearly
alf did not complete the prescribed course. Predictive factors
or RT at EOL were stage IV disease or multiorgan involve-
ent at diagnosis, age <65 years at diagnosis, and treating
nstitution. The population of lung cancer patients was also
he subject of a brief review by Ampil et al.4: speciﬁcally, they
ssessed whether the rapid decline after clinical detection of
rain metastasis warrants immediate hospice referral rather
han palliative RT.
Little else has been elucidated regarding what constitutes
orrect utilization of RT at EOL. Unlike chemotherapy, theretherapy 1 9 ( 2 0 1 4 ) 191–194 193
is no framework in place to validate halting radiation therapy
either in the name of overutilization or futility. In order to deci-
pher whether or not RT practices at the EOL are warranted, we
ﬁrst need to characterize the frequency of the practice, as we
have done here. This study provides a look into the results
among an unﬁltered patient population receiving radiation
therapy in the late stage of disease. Here we  show that there is
little inter-institutional variance in radiotherapy utilization at
EOL between these two centers. In both patient groups the pro-
portion of patients receiving radiation therapy within a month
of death was 6–7%.
Conversely, some may argue that since only 6–7% of all
patients treated in 2010 died within 30 days of RT, that 93–94%
of patients did not, and that nothing need change. The point
of emphasis perhaps should be what cutoff is used: if we  use
RT within 7 days of death as a benchmark, 2–3% of patients
treated in 2012 at these two sites meet that criterion. Deter-
mining what is ‘too many’  or ‘too few’ requires a national
discussion and clearly is beyond the purview of this bench-
marking manuscript. However, important issues that must be
addressed include patients’ and their family’s acceptance of
active treatment cessation in the context of palliative care,
as well as physicians’ inexact ability to prognosticate the
patient’s time of death.
It is unlikely that these data will quickly expand Ameri-
can hospice utilization to the last 6 months of life. As a start,
we propose that physicians should consider ceasing therapy
earlier in the terminal ill patient with worsening performance
status and multiple signs of clinical deterioration, with the
goal of transitioning care toward comfort measures and with
the hope of avoiding ineffective treatment delivery in the last
4 weeks of life. From these data, we would propose to reduce
that RT frequency from 6 to 7% of all patients receiving RT.
The ﬁnancial and physical costs involved mandate that physi-
cians and patients should take greater advantage of hospice
and work together to minimize duration of palliative courses
as far as possible.
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